Defibrillators

The company is trading at about 19 times earnings for the fiscal year ending in April 2008, and about 16 times estimated earnings for fiscal 2009, well below the historical valuations for its peer group.

Yet Muzzey says it should be able to produce double-digit earnings growth.

The biggest risk he associates with Medtronic is the possibility the company might not achieve the kind of earnings growth that differentiates it from the crowd, Muzzey said.

He is still buying these shares for new accounts and says they should be able to provide a better return than the market average over the next few years.

Buy a link here From the April 23, 2007 editions of the Milwaukee Journal Sentinel Have an opinion on this story?

Write a letter to the editor or start an online forum.Subscribe today and receive 4 weeks free!

Sign up now.

BACK TO TOP News Privacy Policy Journal Sentinel Inc.

is a subsidiary of Journal Communications.

...

Read more...